Pfizer (PFE) Tops Q4 EPS by 1c, FY EPS Guidance Misses Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS
January 29, 2019 6:45 AM ESTPROVIDES 2019 FINANCIAL GUIDANCE
Full-Year 2018 Revenues of $53.6 Billion, Reflecting 2% Operational Growth; Fourth-Quarter 2018 Revenues of $14.0 Billion, Reflecting 5% Operational Growth Full-Year 2018 Reported Diluted EPS(1) of $1.87, Adjusted Diluted EPS(2) of $3.00; Fourth-Quarter 2018 Reported Loss Per Share(1) of $0.07, Adjusted Diluted EPS(2) of $0.64 Returned $20.2 Billion Directly to Shareholders in 2018 Through Share Repurchases and Dividends; Anticipates Repurchasing Approximately $9 Billion of Shares in 2019 Provides 2019 Financial Guidance Reflects a Full Year of Revenue and Expense Contributions from Consumer Healthcare(3) Reflects Anticipated Unfavorable Impact of Foreign Exchange of... More